Peer-reviewed veterinary case report
Doxorubicin with heat treatment tested in dogs with solid tumors
By Hauck, Marlene L et al.·Published in Clinical cancer research : an official journal of the American Association for Cancer Research·2006·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors.
- Species:
- dog
Plain-English summary
A group of dogs with solid tumors, including sarcomas and carcinomas, were treated with a new form of chemotherapy called doxorubicin encapsulated in low temperature sensitive liposomes (LTSL) along with local heat therapy. The treatment aimed to improve drug delivery to the tumors and was given in three sessions over several weeks. While some dogs experienced side effects like low white blood cell counts and liver issues, the treatment was generally well tolerated. Out of the dogs that received multiple doses, some showed stable disease or even a partial response to the treatment, suggesting it could be a promising option for managing these types of tumors.
People also search for: dog cancer treatment options · doxorubicin for dogs · canine sarcoma treatment · side effects of chemotherapy in dogs
Abstract
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16818699/